Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tianma Xingnao Capsule is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of cognitive impairment and neurological symptoms. It is composed of several herbal extracts, with *Gastrodia elata* (Tianma) serving as a principal component. The capsule is indicated for vascular mild cognitive impairment (vMCI), particularly in patients presenting with the TCM syndrome of kidney deficiency and phlegm turbidness. Its therapeutic mechanism is thought to involve neuroprotection, improvement of cerebral blood circulation, and modulation of neurotransmitter systems. It is currently being evaluated in Phase 4 clinical trials in China to compare its efficacy against other TCM treatments like Compound Cistanche Yizhi capsules.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tianma Xingnao Capsule.